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DEPARTMENT OF MANAGED
HEALTH CARE
Director: Shelley Rouillard ♦ (916) 324-8176 ♦ Help Center: (888) 466-2219 or 
www.HealthHelp.ca.gov ♦ Internet: www.dmhc.ca.gov
Created on July 1, 2000, the Department of Managed Health Care(DMHC) regulates the managed care industry in California. Thecreation of DMHC resulted from Governor Gray Davis’s approval of
AB 78 (Gallegos) (Chapter 525, Statutes of 1999), one component of a 21-bill package
signed by the Governor in 1999 to reform the regulation of managed care in the state. The
Department is created in Health and Safety Code section 1341; DMHC’s regulations are
codified in Title 28 of the California Code of Regulations (CCR).
DMHC administers the Knox-Keene Health Care Service Plan Act of 1975, Health
and Safety Code section 1340 et seq., which is intended to promote the delivery of health
and medical care to Californians who enroll in or subscribe to services provided by a health
care service plan. A “health care service plan” (health plan)—more commonly known as a
health maintenance organization (HMO) or managed care organization (MCO)—is defined
broadly as any person who undertakes to arrange for the provision of health care services
to enrollees or members, or to pay for or reimburse any part of the cost for those services,
in return for a prepaid or periodic charge paid by or on behalf of the enrollees or members. 
In Health and Safety Code section 1342, the legislature has expressly instructed the
Department Director to ensure the continued role of the professional as the determiner of
the patient’s health needs; ensure that enrollees and members are educated and informed
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of the benefits and services available in order to make a rational consumer choice in the 
marketplace; prosecute malefactors who make fraudulent solicitations or who use 
misrepresentations or other deceptive methods or practices; help to ensure the best possible
health care for the public at the lowest possible cost by transferring the financial risk of 
health care from patients to providers; promote effective representation of the interests of
enrollees and members; ensure the financial stability of health plans by means of proper
regulatory procedures; ensure that enrollees and members receive available and accessible
health and medical services rendered in a manner providing continuity of health care; and
ensure that subscribers and enrollees have their grievances expeditiously and thoroughly 
reviewed by DMHC.
The Director of DMHC is appointed by, and serves at the pleasure of, the Governor. 
The Department’s staff of attorneys, financial examiners, health plan analysts, physicians 
and other health care professionals, consumer service representatives, and support staff
assist the DMHC Director in licensing and regulating more than 130 health plans in
California. Licensed health plans include HMOs and other full-service health plans, as well
as several categories of specialized health plans (including prepaid dental, vision, mental
health, chiropractic, and pharmacy plans). DMHC-licensed health plans provide health care 
services to approximately 26 million California enrollees.
Created in Health and Safety Code section 1374.30 et seq., DMHC’s independent
medical review (IMR) system allows health plan enrollees to seek an independent review
when medical services are denied, delayed, or otherwise limited by a plan or one of its
contracting providers, based on a finding that the service is not medically necessary or
appropriate. The independent reviews are conducted by expert medical organizations
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independent of plans and certified by an accrediting organization, pursuant to conflict of
interest provisions. An IMR determination is binding on the plan, and the Department will
enforce it. 
SB 260 (Speier) (Chapter 529, Statutes of 1999) added section 1347.15 to the
Health and Safety Code to create the Financial Solvency Standards Board (FSSB). FSSB
advises the DMHC Director on matters of financial solvency affecting the delivery of
health care services, and develops and recommends financial solvency requirements and
standards relating to plan operations, plan-affiliate operations and transactions, plan-
provider contractual relationships, and provider-affiliate operations and transactions. 
Comprised of the DMHC Director and seven members appointed by the Director, FSSB
also periodically monitors and reports on the implementation and results of those
requirements and standards, and reviews proposed regulation changes.
DMHC houses the Help Center, which is open 24 hours a day, 365 days a year, and
functions in many languages to help consumers who experience problems with their HMO. 
The Help Center educates consumers about their health care rights, resolves consumer
complaints, helps consumers navigate and understand their coverage, and ensures access 
to appropriate health care services. The DMHC Help Center provides direct assistance to
health care consumers through a call center and online access. DMHC is funded by 
assessments on its regulated health plans.
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Essential Healthcare Benefits Regulation 
Approved by OAL 
On June 27, 2017, the Office of Administrative Law (OAL) approved DMHC’s
proposed amendments to section 1300.67.005, Title 28 of the CCR, to establish revised 
essential health benefits under the federal Affordable Care Act (ACA) in California.
Enacted in 2010, the ACA required the Secretary of the U.S. Department of Health 
and Human Services (DHHS) to define “essential health benefits” (EHB), which are a 
minimum standard for health benefit coverage under ACA sections 1301 and 1302 (42 
U.S.C. sections 18021 and 18022). DHHS issued guidance for state implementation of
EHB in 2011; that guidance authorized each state to select a base-benchmark plan from a
list of options to establish EHB particular to that state. Pursuant to those federal guidelines,
the California legislature enacted AB 1453 (Monning) (Chapter 854, Statutes of 2012), 
which established Health and Safety Code section 1367.005; that statute established the
California EHB benchmark plan by selecting the Kaiser Small Group HMO 30 plan as that
plan was offered in 2012. Section 1367.005 also supplemented the base-benchmark plan 
by establishing requirements for pediatric dental and vision benefits and coverage of
habilitative and mental health services. To comply with AB 1453, DMHC originally 
adopted section 1300.67.005 as an emergency regulation in July 2013; it permanently 
adopted that section in April 2014.
More recently, in 2015, DHHS directed states to select a new base-benchmark plan 
from options offered during the first quarter of 2014, and to supplement that base-
benchmark as necessary to achieve coverage in all ten broad, federally defined EHB 
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categories (such as pediatric oral and vision care). Accordingly, the California legislature 
enacted SB 43 (Hernandez) (Chapter 648, Statutes of 2015) in order to define the new base-
benchmark plan as the Kaiser Small Group HMO 30 as that plan was offered during the
first quarter of 2014, and to update the EHB standards for rehabilitative/habilitative health 
care services and devices, pediatric benefits, and other EBH standards in accordance with
federal law and guidance. 
To comply with SB 43, DMHC adopted emergency amendments to section 
1300.67.005, effective November 28, 2016; on February 10, 2017, DMHC published
notice of its intent to permanently adopt these amendments without change. According to
DMHC’s initial statement of reasons, the amendments are necessary to interpret,
implement and make specific the requirements for health plan coverage of EHB under
Health and Safety Code section 1367.005, as amended by SB 43.
The newly-effective amendments to section 1300.67.005 clarify and implement the
updated benchmark standard, and ensure consistency with SB 43’s updated EHB standard 
and federal guidance regarding the provision of EHB. It also provides transparency to the
public regarding the benefits that must be covered, and aims to implement the updated 
EHB standard in a manner that allows the Department to efficiently determine compliance.
The approved amendments are identical to those approved as emergency regulations on 
November 28, 2016.
Public Meeting on SB 1052 (Torres)
On August 25, 2017, DMHC held a public meeting to discuss a draft of new section
1300.67.205, Title 28 of the CCR. Draft section 1300.67.205 would implement SB 1052 
(Torres) (Chapter 575, Statutes of 2014), which amended section Health and Safety Code
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section 1363.01 and added new section 1367.205. The latter provision requires DMHC to
collaborate with the Department of Insurance (DOI) to develop—by January 1, 2017—a 
standard formulary template to be utilized by health plans and health insurers that provide
prescription drug benefits and maintain one or more drug formularies.
Under new section 1367.205, such health plans (and insurers subject to DOI
jurisdiction) must do all of the following: (1) post the formulary or formularies for each
product offered by the plan on the plan’s Internet website in a manner that is accessible
and searchable by potential enrollees, enrollees, and providers; (2) update the formularies
on a monthly basis; and (3) no later than six months after the date that a standard formulary
template is developed by DMHC and DOI, the plan must use that template to display the
formulary or formularies for each product offered by the plan. The template developed by 
DMHC and DOI must do all of the following: (1) include information on cost-sharing tiers
and utilization controls, including prior authorization or step therapy requirements, for each 
drug covered by the product; (2) indicate any drugs on the formulary that are preferred over
other drugs on the formulary; (3) include information to educate enrollees about the
differences between drugs administered or provided under a health plan’s medical benefit
and drugs prescribed under a health plan’s prescription drug benefit and about how to 
obtain coverage regarding drugs that are not covered under the plan’s prescription drug
benefit; and (4) include information to educate enrollees that health plans that provide
prescription drug benefits are required to have a method for enrollees to obtain prescription 
drugs not listed in the health plan drug formulary if the drugs are deemed medically
necessary by a clinician.
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Under draft section 1300.67.205, the formulary should include a cover page, table
of contents, informational section, categorical list of prescription drugs, and an index. The
cover page shall include the title of the document; name of the health plan; the name of
each product to which the formulary is applicable; the date the formulary was last updated; 
a direct website link to an electronic version of the formulary posted on health plan’s public
website; contact information for the plan; and a direct website link to specific instructions
for locating plan-specific coverage documents that include cost sharing information
applicable to prescription drugs.
The informational section shall include definitions; instructions on how to locate
prescription drug in the categorical list of prescription drugs; a description of how drugs
are listed; a description of the drug tiers in the formulary; a description of all utilization
management restrictions that the plan imposes on prescription drug coverage; information 
about the differences between drugs covered under the medical benefit and drugs covered
under the prescription drug benefit of the product; a notice that the health plan must make
monthly updates on the formulary; an explanation that the presence of a prescription drug
on the formulary does not guarantee that an enrollee will be prescribed that medication; a 
notice that the health plan must cover nonformulary drugs when medically necessary and 
a detailed description of the process for requesting coverage of a non-formulary drug;
instructions on how to locate a network retail pharmacy to fill a prescription; a detailed
description of the process for requesting prior authorization or an exception to a step
therapy requirement; notice of an enrollee’s rights concerning step therapy; notice that a
health plan may not limit or exclude coverage for a drug if it was previously approved and 
the provider continues to prescribe the drug for the medical condition; a description of the
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limit on cost sharing for orally administered anti-cancer drugs; a detailed description of the 
process for requesting coverage and obtaining drugs that are limited to restricted specialty
pharmacy access or are subject to other network limitations (as applicable); and an 
annotated legend or key to all abbreviations, symbols, and notations used in the formulary.
The categorical list of prescription drugs must be organized by drug category and
class based on a commonly used and widely accepted drug classification system; include a
complete list of all covered prescription drugs; include columns which distinguish
prescription drug name, drug tier, and coverage requirements and limits; list the proprietary 
name for a brand name drug in all capital letters in the “prescription drug name” column;
and include all covered dosage forms and strengths for each prescription drug. The “drug 
tier” column should include the cost sharing tier in which the prescription drug is placed.
The “coverage requirements and limits” column should include abbreviations or symbols
for all utilization management restrictions that the health plan imposes on prescription drug 
coverage. The annotated legend or key to all abbreviations, symbols, and notations used in
the formulary must appear on each page of the categorical list.
Finally, the index must list each covered brand name and generic drug by brand
name in alphabetical order and include the page number for the location of the drug in the
categorical list of prescription drugs. 
At this writing, neither DMHC nor DOI has published proposed regulations to
implement SB 1052.
Public Meetings on AB 72 (Bonta)
On June 26 and September 12, 2017, DMHC held stakeholder meetings on its
proposed implementation of AB 72 (Bonta) (Chapter 492, Statutes of 2016), parts of which
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took effect on July 1, 2017. AB 72 protects consumers from surprise medical bills when
they go to in-network facilities, such as hospitals, labs, or imaging centers and receive non-
emergency services from a non-contracted provider. Effective July 1, 2017, AB 72 enacted
Health and Safety Code section 1371.9, which requires that if an enrollee receives covered
health care services from an in-network facility at which, or as a result of which, the
enrollee receives services from a non-contracted individual health professional, the
enrollee shall pay no more than the same amount the enrollee would have paid if the health
care services were received from a contracted individual health professional. Health plans 
were required to have this provision in their contracts on or after July 1, 2017.
AB 72 also added section 1371.31 to the Health and Safety Code, which creates— 
effective July 1, 2017—a default reimbursement rate for non-contracting providers, which
is the greater of 125% of the Medicare rate or the “average contracted rate” (ACR).
Thereafter, the new section requires DMHC—by January 1, 2019—to develop a
standardized methodology for calculating the ACR paid to non-contracting providers. 
Finally, AB 72 added new section 1371.30 to the Health and Safety Code, which 
required DMHC—by September 1, 2017—to establish an independent dispute resolution
process (IDRP) for the purpose of processing and resolving a claim dispute between a
health plan and a non-contracting individual health professional for services subject to
section 1371.9. The bill authorizes DMHC to contract with one or more independent
organizations to conduct the AB 72 IDRP, and DMHC’s IDRP is conducted electronically
through a web-based portal that is managed by MAXIMUS Federal Services, Inc.
DMHC has created an AB 72 Non-Emergency Services IDRP Application form
and cautions that eligible claim disputes that are subject to DMHC jurisdiction under AB
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72 must meet all of the following criteria: (1) the disputed claim must be for services
rendered on or after July 1, 2017; (2) the disputed claim must be for non-emergency
services; if there is an unresolved dispute as to whether the health care service(s) at issue 
is non-emergent, the claim does not qualify for the AB 72 IDRP; (3) the disputed claim
must be for covered services provided at a contracting health facility, or provided as a result
of covered services at a contracting health facility, by a non-contracting individual health 
professional; (4) the non-contracting provider has completed the health plan or payor’s
Provider Dispute Resolution (PDR) process within the last 365 days; (5) the non-
contracting provider is not a dentist; and (6) the payor is not a Medi-Cal managed health
care service plan or any other entity that enters into a contract with the State Department
of Health Care Services.
At the public meetings, DMHC staff walked attendees through definitions of
various terms used in AB 72 and the regulation timeline under which the Department will
develop regulations containing the standardized methodology for calculating the ACR to 
be paid to non-contracting providers. At this writing, DMHC has not yet initiated that
rulemaking process.
2016 Annual Report
On June 17, 2017, DMHC released its 2016 annual report, which includes an 
enrollment overview, the implementation of DMHC’s Health Plan Dashboard, statistics on
the Help Center, plan licensing, plan monitoring, financial oversight, rate review and
enforcement against health care insurers and agents. Overall, DMHC assisted with over 
164,000 phone inquiries, 14,000 consumer complaints, 5,300 independent medical review
cases, and 4,819 non-jurisdictional referrals.
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♦ Enrollment Overview. In 2016, full service health plan enrollment was over 25 
million; enrollment in specialized plans reached 30 million. Health plan enrollment has
shifted from primarily commercial enrollment to more evenly distributed enrollment
between commercial and government enrollment. 
♦ Help Center and Health Plan Dashboard. In 2016, DMHC’s Help Center
assisted over 188,000 health care consumers, received over 14,000 complaints, and closed
over 5,000 independent medical reviews. DMHC also implemented the “Health Plan
Dashboard,” an online tool created to increase public accessibility to health plan 
information and data. The data compiled includes information on health plans licensed by 
DMHC, enrollment, financial reports, premium rates, consumer complaints, audit reports,
and DMHC enforcement actions. The Dashboard feature also provides an overview of the
health plan industry, and provides information on enrollment, financial reports, premium
rates, consumer complaints, and enforcement. With these items tracked, consumers can
compare their health plans to others. During 2016, frequent consumer complaints included
coverage cancellation, billing problems, quality of service, coordination of care, and other
coverage concerns. Most concerns are resolved through the standard complaint process.
Independent medical review is available if a health plan denies, modifies, or delays a
request for services as not medically necessary, experiential, or investigational.
♦ Plan Licensing. DMHC issues licenses to health plans in California and reviews
health plan mergers to ensure adherence with Knox-Keene Act consumer protection and
financial solvency requirements. In 2016, DMHC approved the merger of Centene’s
acquisition of Health Net and Aetna’s acquisition of Humana (later barred by the U.S.
Department of Justice).
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♦ Plan Monitoring. The Office of Plan Monitoring (OPM) was created and
implemented in 2016 to improve oversight of health plan care and delivery systems in
compliance with the Knox-Keene Act. Specifically, OPM oversees access to health care,
utilization management, quality improvement, continuity and coordination of care,
language access, and enrollee grievance and appeals. DMHC monitors provider networks
and accessibility of services to enrollees, physician-patient ratios, and compliance with its
timely access to health care regulations. DMHC additionally conducted ten surveys of
commercial full-service health plans as a continuation of the Paul Wellstone and Pete 
Domenci Mental Health Parity and Addiction Equity Act. 
♦ Financial Oversight. In 2016, DMHC uncovered 230,000 unprocessed claims
for services provided to consumers under the L.A. Care Health Plan. DMHC worked with
L.A. Care to ensure the claims were processed by July 2016. The total amount paid to 
providers was $10.01 million plus an additional $900,000 in interest. This is the largest
claims payment remediation resulting from a DMHC financial examination.
♦ Rate Review. In 2016, DMHC reviewed 47 individual and small group rate
filings. DMHC convinced Aetna Health of California, Inc. to reduce its proposed rate hike
(see below) and saved small group consumers around $1.3 million. 
♦Enforcement. In 2016, DMHC took numerous enforcement actions against health
plans and agents who solicit business for health care services. For example, DMHC fined
Anthem Blue Cross $700,000 and ordered corrective action for improperly cancelling
health coverage to 69 individuals from May 2013–December 2014. 
DMHC also imposed a penalty against Kaiser Foundation Health Plan, Inc. for its
refusal to approve an enrollee’s request for a second opinion from an out-of-network
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specialist. DMHC additionally imposed fines regarding grievance system violations to both 
Anthem Blue Cross ($1 million) and Kaiser Permanente ($195,000). Blue Shield of
California was also awarded a fine of $125,000 for misconduct during the independent
medical review process. Lastly, DMHC took enforcement action against solicitors or
insurance agents who engaged in fraudulent or dishonest dealings with the public while
enrolling consumers in health plan products. 
Recent Enforcement Actions
Following is a description of other recent enforcement actions taken by DMHC:
♦ Fines against Health Net for violating antidiscrimination laws. On July 24, 
2017, DMHC issued a total of $200,000 in fines against Health Net after it discovered the 
plan denied health services to members of the transgender community in previous years.
DMHC found that Health Net had violated antidiscrimination laws by denying coverage to 
several patients who attempted to obtain gender reassignment surgeries. Health Net
maintained it believed the surgeries to be cosmetic and, in some cases, based the denial on
exclusions or limitations in the patient’s plan because of their transgender status (a 
violation of California’s Insurance Gender Nondiscrimination Act, codified at Health and 
Safety Code section 1365.5). 
♦ Kaiser Permanente’s provision of behavioral health care services. On July 18,
2017, DMHC and Kaiser Foundation Health Plan, Inc. (Kaiser Permanente) announced a 
settlement agreement concerning Kaiser’s inadequate provision of access to mental health
services, which DMHC identified in its 2015 and 2017 routine survey reports. Kaiser is 
expected to meet the deliverables and benchmarks outlined in the settlement agreement or
be subject to a $1 million fine. Kaiser is also expected to re-work its Behavioral Health
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Quality Assurance Program to mitigate accessibility issues. Kaiser will contract with an
expert consultant for advice on how to improve oversight of its behavior health system.
The stipulation requires Kaiser to pay for a behavioral health care consultant and, in good
faith, consider their recommendations. Kaiser will be required to work with the consultant
for one to three years. The corrective action plan includes improvements to documentation 
of Kaiser’s quality improvement efforts for access compliance, improvements in
transparency in behavioral health appointment access, implementation of a policy that all
members who are not offered timely access to services are reviewed for risk and ensured
their needs are taken care of, implementation of monitoring systems to track access of
follow-up appointments, internal corrective action plan development that documents the
extent of root cause analysis and corrective action interventions, and improved integration
of external provider access data and oversight. Monetary fines will be imposed if Kaiser
fails to meet a benchmark or deliverable.
Anthem Lowers Rate Increase in Response to 
DMHC 
In mid-October 2017, Anthem Blue Cross agreed to lower two planned premium
increases for 2018 when DMHC questioned Anthem’s cost prediction. Anthem previously
argued that Californians were estimated to ingest a significantly higher amount of
prescription medication in 2018 and used this to justify a 30% increase in prescription drug 
costs for 2018. Anthem later announced it would reduce its planned premium increases for
2018 by $114,000,000. 
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DMHC Studying Federal Regulations Regarding 
Contraceptive Coverage 
On October 6, 2017, DMHC issued a statement on federal regulations regarding
contraception coverage. Director Shelley Rouillard stated that the DMHC is currently
reviewing the details of new federal regulations and possible impacts to Californians
enrolled in plans licensed by the DMHC. California has a long history of expanding timely
access to birth control to prevent unintended pregnancy, and has enacted laws that promote 
gender equity and women’s health. State-regulated health plans must cover contraceptives
for women without cost sharing, with very few exceptions offered for religious employers
as defined in California law. Hundreds of thousands of women throughout the United
States are eligible to receive most methods of birth control at no cost under the Affordable
Care Act’s essential health benefits requirement. However, the Trump Administration’s
executive order signed October 12, 2017 expands the number of employers and insurers
that qualify for exemptions from the requirement of having to provide birth control by 
asserting a religious or moral objection.
LEGISLATION
SB 223 (Atkins), as amended September 5, 2017, amends section 1367.04 and adds
section 1367.042 to the Health and Safety Code regarding language assistance services and
qualifications for interpreters provided by health plans to enrollees with limited English
proficiency (LEP).
Amended section 1367.04 requires health plans to provide written notice in 
specified documents of the availability of interpretation services in the top fifteen 
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languages spoken by LEP individuals in California, identified annually as determined by 
the Department of Health Care Services. The amendments to section 1367.04 require
interpreters to have demonstrated proficiency in English and the target language, and 
knowledge in both English and the target language of health care terminology and concepts
relevant to health care delivery systems. Additionally, an interpreter must adhere to 
generally accepted interpreter ethics and principles, including client confidentiality. The
amendments also prohibit an enrollee from being required to provide his/her own 
interpreter, rely on an adult or minor child for interpretation services, or rely on a staff 
members who does not meet the new requirements for interpreters.
New section 1367.042 requires health plans to notify enrollees and members of the
public of all of the following information: (1) the availability of language assistance
services, including oral interpretation and translated written materials, and how to access
these services free of charge and in a timely manner; (2) the availability of appropriate
auxiliary aids and services, including qualified interpreters for individuals with disabilities
and information in alternate formats; (3) the health plan does not discriminate on the basis
of race, color, national origin, ancestry, religion, sex, marital status, gender, gender
identify, sexual orientation, age, or disability; (4) the availability of a grievance procedure,
how to file a grievance, and how to submit the grievance to DMHC after completing the
grievance process or participating in it for at least 30 days; and (5) how to file a 
discrimination complaint with the DHHS Office of Civil Rights. The new section requires
health plans to provide this information to enrollees upon initial enrollment and annually
thereafter. The section also requires that the information be provided in a conspicuously
visible location in the evidence of coverage; in or with materials that are routinely
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disseminated to the plan’s enrollees at least annually; and on the plan’s Internet website in
a manner that allows enrollees, prospective enrollees, and members of the public to easily
locate the information. Governor Brown signed SB 223 on October 13, 2017 (Chapter 771, 
Statutes on 2017).
SB 17 (Hernandez), as amended on September 5, 2017, adds and amends
numerous sections of the Health and Safety Code to promote transparency in prescription 
drug pricing, to enable measurement of the impact of prescription drug costs on the overall
health plan premium, and to provide information on prescription drug price increases to 
patients, state programs, employers, and other payers. 
Beginning October 1, 2018, new section 1367.245 requires health plans that report 
rate information to DMHC through the existing small and large group rate review process 
to also report annually to DMHC the following information on all covered prescription 
drugs: (1) the 25 most frequently prescribed drugs; (2) the 25 most costly drugs by total
annual spending; and (3) the 25 drugs with the highest year-over-year increase in total 
annual spending. The new section also requires DMHC to compile this information into a
report for the public and legislators, and—beginning January 1, 2019—to post that report
on its website. 
The amendments to section 1385.045 require health plans to annually report to 
DMHC the following information on specified prescription drugs: (1) the percentage of the 
premium attributable to prescription drug costs for the prior year for each category of 
prescription drugs; (2) the year-over-year increase, as a percentage, in per-member, per-
month total health plan spending for each category of prescription drugs; (3) the year-over-
year increase in per-member, per-month costs for drug prices compared to other
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components of the health care premium; (4) the specialty tier formulary list; (5) the
percentage of the premium attributable to prescription drugs administered in a doctor’s
office that are covered under the medical benefit as separate from the pharmacy benefit, if
available; and (6) information on the plan’s use of a pharmacy benefit manager (PBM), if
any, including its name and which components of the prescription drug coverage are 
managed by the PBM.
SB 17 also adds new Chapter 9 (commencing with section 127675) to the Health
and Safety Code, which requires manufacturers of certain prescription drugs that are
purchased by state-regulated programs (including licensed health plans) to notify the state
at least 90 days in advance of the planned effective date of an increase in the wholesale
acquisition cost of those drugs under specified circumstances. Governor Brown signed SB
17 on October 9, 2017 (Chapter 603, Statutes on 2017). 
AB 1316 (Quirk), as amended September 1, 2017, amends section 1367.3 of the
Health and Safety Code to clarify the circumstances under which health plans must cover
screening for lead poisoning in children. The amendments require health plans that cover
hospital, medical, or surgical expenses on a group basis to cover screening for blood lead
levels in children of any age who are at risk for lead poisoning if that screening is prescribed
by a health care provider (including physicians, nurse practitioners, and physician
assistants) affiliated with the plan. Governor Brown signed AB 1316 on October 5, 2017
(Chapter 507, Statutes of 2017). 
AB 1048 (Arambula), as amended September 8, 2017, adds section 4052.10 to the
Business and Professions Code to permit pharmacists—beginning July 1, 2018—to 
dispense a Schedule II controlled substance as a partial fill (defined as a part of a
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prescription filled that is of a quantity less than the entire prescription). Additionally, the
bill adds section 1367.43 to the Health and Safety Code, which requires health plans— 
commencing July 1, 2019—to prorate an enrollee’s cost sharing for a partial fill of a
prescription dispensed pursuant to Business and Professions Code section 4052.10. Section
1367.43 applies only to oral, solid dosage forms of prescription drugs. AB 1048 is intended
to prevent the over prescription of opioids and minimize the number of pills available for
unintentional or intentional diversion. Governor Brown signed AB 1048 on October 9,
2017 (Chapter 615, Statutes of 2017).
SB 133 (Hernandez), as amended September 12, 2017, and as it relates to DMHC,
amends section 1373.96 of the Health and Safety Code to require a health plan, at the
request of a newly covered enrollee under an individual health care service plan contract,
to arrange for the completion of covered services as set forth in existing law by a
nonparticipating provider if the newly covered enrollee’s prior coverage was terminated
under certain circumstances (including when a health benefit plan is withdrawn from any 
portion of a market). The bill also requires health plans to provide notice as to the process
by which an enrollee may request completion of covered services at the time the plan sends
a notice of termination of coverage notice to the enrollee. SB 133 is intended to ensure
continuity of care to enrollees suffering from a serious chronic condition and whose health
plan withdraws from a particular market while the enrollee is undergoing treatment.
Governor Brown signed SB 133 on October 4, 2017 (Chapter 481, Statutes of 2017). 
AB 1074 (Maienschein), as amended August 24, 2017, amends section 1374.73 of
the Health and Safety Code, which requires health plans to provide coverage for behavioral
health treatment (BHT) for pervasive developmental disorder or autism provided by a 
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qualified autism service professional supervised and employed by a qualified autism
service provider. AB 1074 revises those provisions to require a qualified autism service 
professional or a qualified autism service paraprofessional to be supervised by a qualified
autism service provider for purposes of providing BHT. The bill requires a qualified autism
service professional and a qualified autism service paraprofessional to be employed by a
qualified autism service provider or an entity or group that employs qualified autism
service providers. The bill additionally authorizes a qualified autism service professional
to supervise a qualified autism service paraprofessional. The bill also revises the definition
of a “qualified autism service professional” to, among other things, specify that the BHT
provided by the qualified autism service professional may include clinical case 
management and case supervision under the direction and supervision of a qualified autism
service provider. According to the author, the bill is intended to update existing law relating
to providers of BHT for children with autism to reflect existing practices and changes in
the field, and remove unnecessary barriers and increase access to care. Governor Brown
signed AB 1074 on September 30, 2017 (Chapter 385, Statutes of 2017). 
SB 562 (Lara and Atkins), as amended May 26, 2017, would add Title 22.2 to the
Government Code to enact “The Healthy California Act.” The Healthy California Act
would require a comprehensive universal single-payer health care coverage system for all
Californians. The bill is not to become effective until the Secretary of Health and Human
Services establish funding for the implementation of the bill.
SB 562 would require Healthy California to be governed by an unpaid executive
board comprised of nine members appointed by the Governor and legislature. It would also
require the executive board members to have demonstrated knowledge, evident expertise
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in health care, and would require four members from a nurse labor organization, the general
public, a labor organization, and the medical provider community. The bill would permit 
all Californians residents to be eligible and entitled to enroll. “Resident” is defined as an
individual whose primary dwelling is in the state and without regard to that individual’s
immigration status. Enrollees of Healthy California would not be required to pay any
premium, co-payments, co-insurance, deductible and any other form of cost sharing for all
covered benefits.
SB 562 would require all medical care determined to be medically appropriate by 
the member’s health care provider. This would include all services provided by Medi-Cal,
essential health benefits (from the Affordable Healthcare Act), and all health plan- or
insurance-mandated benefits. Benefits shall include: chiropractic, vision, dental, ancillary
health or social services (previously covered by a regional center), skilled nursing facility
care, and therapies shown by the National Institutes of Health, National Center for
Complementary and Integrative Health to be safe and effective. [A. Desk]
AB 315 (Wood), as amended July 11, 2017, would add Division 121 (commencing
with section 152000) to the Health and Safety Code regarding pharmacy benefit
management. The new division would require pharmacy benefit managers (PBM) to 
register with DMHC prior to conducting business within California. DMHC would be
required to develop a registration form, and would be authorized to charge a fee for
registration and to suspend a registration of a PBM under specified circumstances. This bill 
would also require a PBM to exercise a duty of good faith and fair dealing in the
performance of its contractual duties to a purchaser, and would require a PBM to disclose
to a purchaser any conflict of interest that would interfere with the discharge of that duty.
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The bill would require a PBM to periodically disclose to a purchaser, at the purchaser’s
request, certain information such as drug acquisition cost, rebates received from
pharmaceutical manufacturers, and rates negotiated with pharmacies. The bill would
require a PBM to notify a pharmacy network provider of certain material contract changes
at least 30 days before those changes take effect, and would prohibit a PBM from notifying 
an individual receiving benefits through that PBM that a pharmacy has been terminated 
from its network until the required notice has been provided to the pharmacy. The bill 
would prohibit a PBM from including in a contract with a pharmacy network provider
provisions that prohibit the provider from informing consumers of alternative medication
options or from dispensing a certain amount of prescribed medication, as specified. The
bill would apply these provisions to a contract or contractual relationship between a PBM
and a purchaser or between a PBM and a pharmacy network provider that is entered into,
issued, amended, renewed, or delivered on or after January 1, 2018. The bill would provide
that these provisions and those relating to registration described above do not apply to a
health plan, health insurer, or related entities that perform PBM services only for enrollees 
of the plan or insureds of the insurer. [S. Inactive File]
LITIGATION
On April 28, 2017, the U.S. Court of Appeals for the District of Columbia issued a 
permanent injunction preventing the merger of Anthem and Cigna in United States, et al.
v. Anthem, Inc., et al., 855 F.3d 345 (D.C. Cir. 2017). The merger would have fused 
together the second and third largest national health insurance carriers. U.S. Circuit Judge
Judith W. Rogers indicated the district court acted within its discretion to permanently
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enjoin the merger and that Anthem failed to demonstrate the type of extraordinary 
efficiencies required to offset the negative impact to market competition that would result
from the merger. Under section 7 of the Clayton Act, 15 U.S.C. section 18, a merger may
not continue between two companies if the market or an activity that impacts the market
would substantially be impacted by less competition. On May 5, 2017, Anthem submitted
a petition for a writ of certiorari to the U.S. Supreme Court; the Court denied that request 
on June 12, 2017.
On April 25, 2017 in Martello v. Rouillard, et al., 689 Fed. Appx. 880 (9th Cir.
2017), the U.S. Ninth Circuit Court of Appeals affirmed the district court’s judgment which
dismissed Jeannette Martello’s complaint. Dr. Martello, a licensed plastic surgeon, has a 
long history of unlawful balance billing practices; DMHC has secured at least two cease 
and desist orders against her, and a trial court imposed $562,000 in civil penalties against 
her in June 2013. At the time she filed the federal court complaint in this matter, she was 
appealing the state court’s orders in the Second District Court of Appeal. In the federal
court matter, Martello challenged the constitutionality of California’s prohibition against
balance billing. She maintained that DMHC and the Medical Board of California’s (MBC)
continued enforcement against her practice of balance billing is unconstitutional and is 
preempted by federal law. Additionally, Martello also sought a permanent injunction to 
enjoin DMHC and MBC from enforcing balance billing laws. Reviewed de novo, the Ninth 
Circuit found the district court properly dismissed Martello’s action under the Younger
doctrine, which states federal courts must not interfere with pending state court proceedings
where the federal action would enjoin state proceedings. 
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Martello was previously disciplined by MBC for her balance billing practices;
MBC found that she had willfully and unlawfully billed patients for emergency services, 
and placed her license on probation for five years.
In a June 12, 2017 unpublished decision, the Second District Court of Appeal
affirmed the dismissal of Martello’s claims against DMHC.
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